Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Engraftment achieved after conditioning without radiation, alkylating agents

Key clinical point: An alemtuzumab/fludarabine conditioning regimen, without any radiation or alkylating agents, was effective in patients with dyskeratosis congenita who experienced myeloid failure.

Major finding: In total, 95% of patients with dyskeratosis congenita achieved primary engraftment at a median of 22 days after transplant.

Study details: A prospective, multicenter study including 20 patients with dyskeratosis congenita aged from 30 months to 65 years.

Disclosures: Dr. Agarwal reported having no conflicts of interest.

Citation:

Agarwal S et al. TCT 2019, Abstract LBA2.